Development and evaluation of luteolin loaded pegylated bilosome: optimization,
Cell Line, Tumor
Cell Survival
/ drug effects
Chemistry, Pharmaceutical
Drug Carriers
/ chemistry
Drug Liberation
Drug Stability
Escherichia coli
/ drug effects
Humans
Intestinal Absorption
Luteolin
/ administration & dosage
Polyethylene Glycols
/ chemistry
Staphylococcus aureus
/ drug effects
Surface Properties
Bilosomes
Box–Behnken’s design
breast cancer
luteolin
pegylated
Journal
Drug delivery
ISSN: 1521-0464
Titre abrégé: Drug Deliv
Pays: England
ID NLM: 9417471
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
22
2
2022
Statut:
ppublish
Résumé
The present research was aimed to develop luteolin (LL) loaded pegylated bilosomes (PG-BLs) for oral delivery. The luteolin bilosomes (BLs) were prepared by the thin-film hydration method and further optimized by the Box-Behnken design (four-factors at three-levels). The prepared LL-BLs were evaluated for vesicle size (VS), PDI, zeta potential (ZP), and entrapment efficiency to select the optimized formulation. The optimized formulation was further assessed for surface morphology, drug release, gut permeation, antioxidant, and antimicrobial study. The cytotoxicity study was conducted on breast cancer cell lines (MDA-MB-231 and MCF7). The optimized formulation LL-PG-BLs-opt exhibited a VS of 252.24 ± 3.54 nm, PDI of 0.24, ZP of -32 mV with an encapsulation efficiency of 75.05 ± 0.65%. TEM study revealed spherical shape vesicles without aggregation. The DSC and XRD results revealed that LL was encapsulated into a PG-BLs matrix. LL-PG-BLs-opt exhibited a biphasic release pattern as well as significantly high permeation (
Identifiants
pubmed: 34866534
doi: 10.1080/10717544.2021.2008055
pmc: PMC8654410
doi:
Substances chimiques
Drug Carriers
0
Polyethylene Glycols
3WJQ0SDW1A
Luteolin
KUX1ZNC9J2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2562-2573Références
Int J Mol Sci. 2020 Jan 15;21(2):
pubmed: 31952316
J Control Release. 2020 Nov 10;327:100-116
pubmed: 32711025
Int J Pharm. 2009 Jul 6;376(1-2):153-60
pubmed: 19394416
Cancers (Basel). 2019 May 06;11(5):
pubmed: 31064156
Eur J Pharm Biopharm. 2020 Sep;154:338-347
pubmed: 32739535
Infect Drug Resist. 2020 Jun 10;13:1697-1711
pubmed: 32606820
J Liposome Res. 2017 Dec;27(4):324-334
pubmed: 27666873
Curr Cancer Drug Targets. 2008 Nov;8(7):634-46
pubmed: 18991571
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):28-51
pubmed: 26456916
Chin Med. 2020 May 1;15:40
pubmed: 32377229
J Pharm Biomed Anal. 2007 Jan 17;43(2):753-7
pubmed: 16930915
J Liposome Res. 2019 Jun;29(2):171-182
pubmed: 30221568
J Clin Med. 2019 Dec 31;9(1):
pubmed: 31906141
Int J Pharm. 2007 Jun 29;338(1-2):317-26
pubmed: 17368984
Int J Pharm. 2015 May 15;485(1-2):329-40
pubmed: 25796122
Drug Dev Ind Pharm. 2017 Jun;43(6):902-910
pubmed: 27977311
Biomed Res Int. 2013;2013:960821
pubmed: 23865076
ACS Omega. 2020 Mar 20;5(12):6461-6471
pubmed: 32258881
J Liposome Res. 2019 Sep;29(3):251-263
pubmed: 30501440
Appl Biochem Biotechnol. 2021 May;193(5):1397-1414
pubmed: 33009585
Microb Pathog. 2020 Feb 11;142:104056
pubmed: 32058023
Int J Nanomedicine. 2019 Aug 15;14:6555-6574
pubmed: 31616143
Methods Mol Biol. 2010;596:467-88
pubmed: 19949937
Drug Deliv. 2016 Jul;23(6):1847-67
pubmed: 25390191
AAPS PharmSciTech. 2012 Dec;13(4):1502-10
pubmed: 23104306
Pharmaceutics. 2013 Oct 25;5(4):542-69
pubmed: 24300562
Drug Deliv. 2021 Dec;28(1):642-654
pubmed: 33787445
J Nat Prod. 2007 Dec;70(12):1889-94
pubmed: 18004816
Evid Based Complement Alternat Med. 2014;2014:732980
pubmed: 25574182
Drug Deliv. 2019 Dec;26(1):820-830
pubmed: 31389248
Br J Pharmacol. 2020 May;177(10):2393-2408
pubmed: 31976547
Mol Med Rep. 2018 Feb;17(2):2456-2464
pubmed: 29207088
Pharm Dev Technol. 2016;21(4):475-86
pubmed: 25831424
BMC Pharmacol Toxicol. 2020 Feb 21;21(1):14
pubmed: 32085802
Int J Nanomedicine. 2011;6:965-74
pubmed: 21720508
Biomed Pharmacother. 2019 Apr;112:108612
pubmed: 30798142
Pharmaceutics. 2021 Apr 29;13(5):
pubmed: 33947103
J Pharm Sci. 2016 Sep;105(9):2949-2958
pubmed: 27209461
Acta Pharm. 2006 Sep;56(3):311-24
pubmed: 19831280
Saudi Pharm J. 2021 Mar;29(3):269-279
pubmed: 33981176